Swiss National Bank’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-32,800
Closed -$297K 2396
2025
Q1
$297K Hold
32,800
﹤0.01% 2387
2024
Q4
$567K Hold
32,800
﹤0.01% 2385
2024
Q3
$524K Hold
32,800
﹤0.01% 2426
2024
Q2
$467K Buy
32,800
+9,800
+43% +$139K ﹤0.01% 2427
2024
Q1
$326K Hold
23,000
﹤0.01% 2494
2023
Q4
$347K Sell
23,000
-2,200
-9% -$32.6K ﹤0.01% 2514
2023
Q3
$398K Hold
25,200
﹤0.01% 2548
2023
Q2
$382K Buy
25,200
+1,500
+6% +$20.7K ﹤0.01% 2578
2023
Q1
$344K Sell
23,700
-2,800
-11% -$37.4K ﹤0.01% 2591
2022
Q4
$358K Buy
+26,500
New +$465K ﹤0.01% 2630

Other funds holding TRDA

Swiss National Bank's TRDA Position: Q2 2025 in Review

Swiss National Bank sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 32,800 shares — an estimated $297K sold.

Swiss National Bank first reported a position in TRDA in Q4 2022 and held it in 10 quarters. The position peaked at $567K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Swiss National Bank reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Swiss National Bank sold 32,800 Entrada Therapeutics shares in Q2 2025, an estimated $297K.
  • Swiss National Bank first reported a position in Entrada Therapeutics in Q4 2022 and held it in 10 quarters.
  • Swiss National Bank's Entrada Therapeutics position peaked at $567K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Swiss National Bank's 13F filing for Q2 2025, filed 12 Aug 2025.